Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA: supplementary materials

Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in

people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies

(DMTs). Patients & methods: Retrospective, observational study of IBM R ? MarketScan R ? claims database.

PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December 2019)

were identified. “Index” was date of alemtuzumab initiation (prescription filled). Results: The study cohort

(n = 341) was primarily female (72%) with (mean ± standard deviation) age 45.1 ± 9.5 years. At index,

duration of MS was 5.3 ± 2.8 years. HCRU (inpatient/outpatient services), outpatient costs (including

MS-specific MRI and emergency room visits) and annualized relapse rate significantly reduced over the 2

years following initiation of alemtuzumab. DMT costs reduced over the same period. Conclusion: Health

economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for

treatment of MS, in this cohort from the USA.